Sign up Australia
Proactive Investors - Run By Investors For Investors

C4X's latest pre-clinical data burnishes the potential of its addiction drug

Orexin-1 is being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders
smoker in monochrome
The firm's lead drug could help the millions of smokers who relapse each year

C4X Discovery Holdings plc (AIM: C4XD) said it had presented pre-clinical data at a leading industry conference that strengthens the evidence base backing the potential of its anti-addiction drug.

Orexin-1 is being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders.

READ: C4X hails progress as it starts to “see the power” of its Taxonomy3 drug discovery platform

On Saturday (Nov 11) at the Neuroscience 2017 meeting, in Washington DC, delegates were furnished with new efficacy stats generated by the company’s lead compound, C4X_3256.

The latest study assessed nicotine self-administration and cue-induced reinstatement; the latter is where strong cravings are triggered by an object or ritual closely associated with taking an addictive substance.

C4X said the latest information supported the development of C4X_3256 as a therapy across two distinct areas of nicotine abuse: smoking cessation and relapse in smokers.

READ: C4X Discovery Holdings says it is on course to become a self-sustaining drugs discovery 'engine'

"This set of studies strengthens C4XD's pre-clinical data package for our lead Orexin-1 antagonist programme,” added the firm’s chief executive, Clive Dix.

“We strongly believe that the programme presents a compelling commercial case for partnership due to its broad applicability to substance use as well as related disorders, such as anxiety, post-traumatic stress disorder, and impulse control.

“This is supported by the high level of pre-clinical partnering interest received that have enabled us to enter late-stage commercial discussions."



Ian_55ae0ddd437b7.jpg
Why Invest In C4X Discovery Holdings plc? Read More Here

Register here to be notified of future C4XD Company articles
View full C4XD profile View Profile

C4X Discovery Holdings plc Timeline

Related Articles

picture of addict
Thu
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
1504120610_biotechLatest.jpg
October 24 2017
The company is poised for a milestone-rich period over the next year or so
Workers at CERN
September 29 2017
The technology being developed is cheaper and smaller than the current units, which are almost prohibitively expensive

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use